论文部分内容阅读
目的观察重组人脑钠肽(rhBNP)对慢性心力衰竭(CHF)患者心率及动脉压的影响。方法 60例CHF患者随机分为对照组(n=32,接受常规抗心衰治疗)和治疗组(n=28,接受常规抗心衰和rhBNP联合治疗),以两组心率、动脉压、尿量、血NT-proBNP水平及射血分数(EF)的差异评价疗效。结果与对照组相比,治疗组用药后24和48 h心率下降,用药后48 h平均动脉压下降,尿量增加,且上述各项差异均有统计学意义(P<0.05)。结论 rhBNP可改善CHF患者的心衰症状作用显著。
Objective To observe the effects of rhBNP on heart rate and arterial pressure in patients with chronic heart failure (CHF). Methods Sixty patients with CHF were randomly divided into control group (n = 32, conventional anti-heart failure treatment) and treatment group (n = 28, conventional anti-heart failure combined with rhBNP treatment) Dose, blood NT-proBNP levels and ejection fraction (EF) were evaluated. Results Compared with the control group, the heart rate of the treatment group decreased 24 and 48 h after treatment, and the mean arterial pressure decreased and the urine output increased 48 h after treatment. All the above differences were statistically significant (P <0.05). Conclusion rhBNP can improve CHF patients with significant effect of heart failure symptoms.